ASH ISTH NHF WFH VWD Guidelines Published

On January 7, 2021, the culmination of a multiyear international collaboration was published in Blood Advances: ASH ISTH NHF WFH Guidelines on the Diagnosis of VWD ASH ISTH NHF WFH Guidelines on...

UniQure Reports Development of Hepatocellular Carcinoma in a Gene Therapy Clinical Trial Participant

Updated 23 December 2020 BioMarin announces no dosing in their hemophilia gene...

COVID-19 vaccination guidance for people with bleeding disorders

Guidance from the World Federation of Hemophilia (WFH), European Association for Haemophilia...

Sanofi to resume dosing in fitusiran clinical studies with protocol amendments

Sanofi has announced plans to resume dosing in its ongoing fitusiran clinical...

CSL Behring to discontinue plasma-derived therapy for hemophilia B

CSL Behring has announced the discontinuation of its plasma-derived factor IX concentrate...

Global dosing hold in fitusiran trials initiated by Sanofi Genzyme to investigate new adverse events
World Federation of Hemophilia | November 6, 2020
A joint statement of the World Federation of Hemophilia (WFH), European Haemophilia Consortium (EHC) and National Hemophilia Foundation (NHF) November 6, 2020 – The WFH,...
Enrollment in gene therapy trials on hold for assessment of interim data: Takeda
World Federation of Hemophilia | November 3, 2020
Takeda has suspended screening and further enrollment in the clinical studies of its AAV8 gene therapies for the treatment of hemophilia A and B. The...
Roche outlines plan for communicating new findings on emicizumab (Hemlibra)
World Federation of Hemophilia | October 9, 2020
In a letter to the global hemophilia community, Roche describes its plan for keeping healthcare professionals and patients informed of new efficacy and safety data...
Roche/Genentech Update on Particles Identified in emicizumab (Hemlibra)
World Federation of Hemophilia | September 17, 2020
Roche and Genentech have announced an update on measures being taken in relation to the translucent silicon oil and protein particles that were identified in...
WFH WBDR 2019 Data Report published
Ellia Tootoonchian | August 31, 2020
After much anticipation, the World Federation of Hemophilia (WFH) World Bleeding Disorders Registry (WBDR) 2019 Data Report has been published. This is the second edition...

Page 1 of 1312 3 4 5 Next ›Last »

Medical news

ASH ISTH NHF WFH VWD Guidelines Published

UniQure Reports Development of Hepatocellular Carcinoma in a Gene Therapy Clinical Trial Participant

COVID-19 vaccination guidance for people with bleeding disorders

Sanofi to resume dosing in fitusiran clinical studies with protocol amendments

CSL Behring to discontinue plasma-derived therapy for hemophilia B

Global dosing hold in fitusiran trials initiated by Sanofi Genzyme to investigate new adverse events

Enrollment in gene therapy trials on hold for assessment of interim data: Takeda

Roche outlines plan for communicating new findings on emicizumab (Hemlibra)

Roche/Genentech Update on Particles Identified in emicizumab (Hemlibra)

WFH WBDR 2019 Data Report published

Recent News

Keywords

Facebook